Legemidler

Lynparza▼ (Olaparib)

ATC
Orphan (smalt) legemiddel
ja

Oppdatert 2 måneder siden

Bondronat (Ibandronsyre)

ATC
Orphan (smalt) legemiddel
Nei

Oppdatert 1 år siden

Perjeta▼ (Pertuzumab)

ATC
Orphan (smalt) legemiddel
Nei

Oppdatert 1 år siden

Fareston (Toremifen)

ATC
Orphan (smalt) legemiddel
Nei

Oppdatert 1 år siden

Myocet (Doksorubicin)

ATC
Orphan (smalt) legemiddel
Nei

Oppdatert 1 år siden

Taxespira (Docetaksel)

ATC
Orphan (smalt) legemiddel
Nei

Oppdatert 1 år siden

Search all legemidler for Brystkreft
 

Kunnskapssoner

En kunnskapssone (KS) på epgonline.org er et område på siden som tilbyr detaljert selvstyrt medisinsk undervisning om en sykdom, tilstand eller prosedyre.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Kunnskapssenter om transplantasjon

Kunnskapssenter om transplantasjon

Se informasjon om best praksis ved solid organtransplantasjon, i tillegg til ekspertdrøftinger om relaterte aktuelle emner.

Fibrinogen Deficiency in Bleeding

Fibrinogen Deficiency in Bleeding

Fibrinogen is important for blood clot formation and breakdown. It is the first coagulant factor to be reduced to critical levels during massive trauma, cardiac surgery and postpartum haemorrhage that involve excessive bleeding. Persistent fibrinogen deficiency can lead to bleeding complications and an increased risk in mortality. This learning zone looks at both congenital and acquired fibrinogen deficiencies including indications and techniques for diagnosis, trigger level for treatment and treatment options.

Last inn mer